The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://gerardsdyi087792.salesmanwiki.com/10138231/glp_3_retatrutide_a_comparative_analysis